Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.50 |
| ▸ | MERTK | Q12866 | 2/20 | 0.49 |
| ▸ | SPHK1 | Q9NYA1 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | AXL | P30530 | 1/20 | 0.48 |
| ▸ | MMP1 | P03956 | 1/20 | 0.47 |
| ▸ | MMP2 | P08253 | 1/20 | 0.47 |
| ▸ | MMP9 | P14780 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12468984 | 0.93 | ALDH1A1 (0.53) | METKDRKMT2AEGFRMERTK | |
| SCHEMBL9304492 | 0.89 | TSHR (0.54) | MEN1KMT2AFAAHSPHK1 | |
| SCHEMBL105644 | 0.88 | ALDH1A1 (0.48) | NPC1RAB9AMETKDRFAAH | |
| SCHEMBL2280125 | 0.86 | MET (0.47) | NPC1RAB9AMETKDRFAAH | |
| SCHEMBL4398555 | 0.86 | GAA (0.53) | METKDREGFRMERTKAXL | |
| SCHEMBL13115623 | 0.85 | ALDH1A1 (0.63) | NPC1RAB9AMETKDRKMT2A | |
| SCHEMBL13906173 | 0.85 | MET (0.48) | METKDREGFRMERTKAXL | |
| SCHEMBL19026688 | 0.85 | MET (0.51) | METKDREGFRMERTKAXL | |
| SCHEMBL13927461 | 0.85 | MET (0.48) | POLBMETKDRMEN1KMT2A | |
| SCHEMBL10202155 | 0.85 | EGFR (0.50) | METKDREGFRMERTKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-02-08 | — | — | US | disclosed |
| US-20180002289-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2018-01-04 | — | — | US | disclosed |
| US-20170275251-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | PHARMORPHIX, A DIVISION OF SIGMA-ALDRICH COMPANY LTD. (GB) | 2017-09-28 | — | — | US | disclosed |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. | 2016-02-04 | — | — | US | disclosed |
| US-20150057310-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | EXELIXIS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | EXELIXIS, INC. (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037552-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | POLB 1400/4885NPC1 577/4885RAB9A 1997/4885 |
| US-20210002228-A1 | Metabolites of N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | NQO2, AURKA, CDC25B | POLB 1861/4885NPC1 1996/4885RAB9A 996/4885 |
| US-20180002289-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, SLC25A11 | POLB 1477/4885NPC1 601/4885RAB9A 2283/4885 |
| US-20120035212-A1 | (L)-Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | MDH1, MDH2, SLC25A11 | POLB 1425/4885NPC1 603/4885RAB9A 2432/4885 |
| US-20150057310-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms therof for the treatment of cancer | MDH2, MDH1, SLC25A11 | POLB 2459/4885NPC1 993/4885RAB9A 2258/4885 |
| US-20170275251-A1 | Malate salt of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer | MDH1, MDH2, ME1 | POLB 1146/4885NPC1 718/4885RAB9A 2288/4885 |
| US-20160031818-A1 | Metabolites of N-(4-phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide | IDH1, NTRK3, FGFR4 | POLB 3321/4885NPC1 968/4885RAB9A 2109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.